B-intervention	0	7	Topical
I-intervention	8	14	silver
I-intervention	15	27	sulfadiazine
O	28	31	for
O	32	35	the
O	36	46	prevention
O	47	49	of
B-condition	50	55	acute
I-condition	56	66	dermatitis
O	67	73	during
O	74	85	irradiation
O	86	89	for
O	90	96	breast
O	97	103	cancer
O	103	104	.

O	105	109	This
O	110	115	study
O	116	121	aimed
O	122	124	to
O	125	133	evaluate
O	134	137	the
O	138	151	effectiveness
O	152	154	of
O	155	162	topical
O	163	169	silver
O	170	182	sulfadiazine
O	183	184	(
O	184	187	SSD
O	187	188	)
O	189	191	in
O	192	202	preventing
O	203	208	acute
O	209	218	radiation
O	219	229	dermatitis
O	230	232	in
O	233	238	women
O	239	248	receiving
O	249	261	radiotherapy
O	262	265	for
O	266	272	breast
O	273	279	cancer
O	279	280	.

O	281	282	A
O	283	293	randomized
O	294	304	controlled
O	305	313	clinical
O	314	319	trial
O	320	323	was
O	324	333	conducted
O	334	336	on
B-eligibility	337	345	patients
I-eligibility	346	350	with
I-eligibility	351	357	breast
I-eligibility	358	364	cancer
I-eligibility	365	373	referred
I-eligibility	374	377	for
I-eligibility	378	390	radiotherapy
I-eligibility	391	396	after
I-eligibility	397	406	treatment
I-eligibility	407	411	with
I-eligibility	412	422	mastectomy
I-eligibility	423	426	and
I-eligibility	427	439	chemotherapy
O	439	440	.

O	441	444	The
O	445	453	patients
O	454	458	were
O	459	469	randomized
O	470	474	into
O	475	478	the
O	479	491	intervention
O	492	493	(
O	493	494	n
O	495	496	=
B-intervention-participants	497	499	51
O	499	500	)
O	501	504	and
B-control	505	512	control
O	513	514	(
O	514	515	n
O	516	517	=
B-control-participants	518	520	51
O	520	521	)
O	522	528	groups
O	529	532	and
O	533	537	were
O	538	548	instructed
O	549	551	on
O	552	559	general
O	560	564	skin
O	565	569	care
O	570	576	during
O	577	589	radiotherapy
O	589	590	.

O	591	594	The
O	595	607	intervention
O	608	613	group
O	614	622	received
O	623	626	SSD
O	627	632	cream
O	633	634	1
O	634	635	%
O	635	636	,
O	637	642	three
O	643	648	times
O	649	650	a
O	651	654	day
O	654	655	,
O	656	657	3
O	658	662	days
O	663	664	a
O	665	669	week
O	669	670	,
O	671	674	for
O	675	676	5
O	677	682	weeks
O	683	689	during
O	690	702	radiotherapy
O	703	706	and
O	707	710	one
O	711	715	week
O	716	726	thereafter
O	726	727	.

O	728	729	A
O	730	737	blinded
O	738	746	observer
O	747	755	assessed
O	756	759	the
O	760	768	severity
O	769	771	of
O	772	782	dermatitis
O	783	789	weekly
O	790	791	(
O	791	794	for
O	795	796	6
O	797	802	weeks
O	802	803	)
O	804	807	and
O	808	814	graded
O	815	817	it
O	818	822	from
O	823	824	0
O	825	827	to
O	828	829	4
O	830	839	according
O	840	842	to
O	843	846	the
O	847	856	Radiation
O	857	864	Therapy
O	865	873	Oncology
O	874	879	Group
O	880	888	criteria
O	888	889	.

O	890	893	The
O	894	897	two
O	898	904	groups
O	905	909	were
O	910	917	similar
O	918	920	in
O	921	929	baseline
O	930	945	characteristics
O	945	946	.

B-cv-bin-abs	947	950	Two
O	951	959	patients
O	960	962	in
O	963	966	the
O	967	974	control
O	975	980	group
B-outcome	981	993	discontinued
O	994	997	the
O	998	1010	radiotherapy
O	1011	1017	course
O	1018	1025	because
O	1026	1028	of
O	1029	1035	severe
O	1036	1040	skin
O	1041	1049	injuries
O	1050	1051	(
O	1051	1057	grades
O	1058	1059	3
O	1060	1063	and
O	1064	1065	4
O	1065	1066	)
O	1066	1067	.

O	1068	1071	The
O	1072	1084	intervention
O	1085	1090	group
O	1091	1102	encountered
O	1103	1116	significantly
O	1117	1121	less
B-outcome	1122	1128	severe
I-outcome	1129	1139	dermatitis
O	1140	1146	during
O	1147	1159	radiotherapy
O	1160	1168	compared
O	1169	1171	to
O	1172	1175	the
O	1176	1184	controls
O	1184	1185	.

O	1186	1189	The
B-outcome	1190	1195	total
I-outcome	1196	1201	score
I-outcome	1202	1204	of
I-outcome	1205	1209	skin
I-outcome	1210	1216	injury
O	1217	1220	was
O	1221	1225	also
O	1226	1231	lower
O	1232	1234	in
O	1235	1238	the
O	1239	1251	intervention
O	1252	1257	group
O	1258	1266	compared
O	1267	1271	with
O	1272	1280	controls
O	1281	1282	(
B-iv-cont-mean	1282	1283	5
I-iv-cont-mean	1283	1284	.
I-iv-cont-mean	1284	1286	49
O	1287	1288	±
B-iv-cont-sd	1289	1290	1
I-iv-cont-sd	1290	1291	.
I-iv-cont-sd	1291	1293	02
O	1294	1296	vs
O	1296	1297	.
B-cv-cont-mean	1298	1299	7
I-cv-cont-mean	1299	1300	.
I-cv-cont-mean	1300	1302	21
O	1303	1304	±
B-cv-cont-sd	1305	1306	1
I-cv-cont-sd	1306	1307	.
I-cv-cont-sd	1307	1309	76
O	1309	1310	,
O	1311	1312	p
O	1313	1314	<
O	1315	1316	0
O	1316	1317	.
O	1317	1320	001
O	1320	1321	)
O	1321	1322	.

O	1323	1324	A
O	1325	1337	multivariate
O	1338	1346	analysis
O	1347	1352	found
O	1353	1357	that
O	1358	1361	the
O	1362	1365	use
O	1366	1368	of
O	1369	1372	SSD
O	1373	1378	cream
O	1379	1380	(
O	1380	1381	p
O	1382	1383	<
O	1384	1385	0
O	1385	1386	.
O	1386	1389	001
O	1389	1390	)
O	1391	1394	and
O	1395	1399	flat
O	1400	1405	chest
O	1406	1410	wall
O	1411	1418	anatomy
O	1419	1420	(
O	1420	1421	p
O	1422	1423	=
O	1424	1425	0
O	1425	1426	.
O	1426	1429	008
O	1429	1430	)
O	1431	1435	were
O	1436	1449	significantly
O	1450	1460	associated
O	1461	1465	with
O	1466	1467	a
O	1468	1477	decreased
O	1478	1482	skin
O	1483	1489	injury
O	1489	1490	.

O	1491	1494	SSD
O	1495	1500	cream
O	1501	1508	reduced
O	1509	1512	the
B-outcome	1513	1521	severity
I-outcome	1522	1524	of
I-outcome	1525	1534	radiation
I-outcome	1534	1535	-
I-outcome	1535	1542	induced
I-outcome	1543	1547	skin
I-outcome	1548	1554	injury
O	1555	1563	compared
O	1564	1568	with
O	1569	1576	general
O	1577	1581	skin
O	1582	1586	care
O	1587	1592	alone
O	1592	1593	.

O	1594	1601	Further
O	1602	1609	studies
O	1610	1612	in
O	1613	1621	patients
O	1622	1626	with
O	1627	1632	other
O	1633	1638	types
O	1639	1641	of
O	1642	1648	cancer
O	1649	1652	and
O	1653	1657	also
O	1658	1667	comparing
O	1668	1671	SSD
O	1672	1677	cream
O	1678	1682	with
O	1683	1688	other
O	1689	1696	topical
O	1697	1703	agents
O	1704	1707	are
O	1708	1717	warranted
O	1717	1718	.
